Chitotriosidase and soluble IL‐2 receptor: Comparison of two markers of sarcoidosis severity

Bargagli, Elena; Bianchi, Nicola; Margollicci, Maria; Olivieri, Carmela; Luddi, Alice; Coviello, Giuseppe; Grosso, Salvatore; Rottoli, Paola

doi:10.1080/00365510701854975

Cited by 59 publications

(42 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Corticosteroid therapy has an independent effect on the ACE level, making serial studies of limited value in treated patients (76,77). Other markers of disease activity, including soluble IL-2 receptor and chitotriosidase (78,79), may prove more useful markers of activity; however, more information about changes in these markers over time and with therapy are still needed (80).…”

Section: Diagnosismentioning

confidence: 99%

A Concise Review of Pulmonary Sarcoidosis

Baughman

Culver²,

Judson

2011

Am J Respir Crit Care Med

438

330

View full text Add to dashboard Cite

This is an update on sarcoidosis, focusing on etiology, diagnosis, and treatment. In the area of etiopathogenesis, we now have a better understanding of the immune response that leads to the disease as well as genetic factors that modify both the risk for the disease and its clinical outcome. Several groups have also identified possible agents as a cause for sarcoidosis. Although none of these potential causes has been definitely confirmed, there is increasing evidence to support that one or more infectious agents may cause sarcoidosis, although this organism may no longer be viable in the patient. The diagnosis of sarcoidosis has been significantly aided by new technology. This includes the endobronchial ultrasound, which has been shown to increase the yield of needle aspiration of mediastinal and hilar lymph nodes. The positive emission tomography scan has proven useful for selecting possible biopsy sites by identifying organ involvement not appreciated by routine methodology. It has also helped in assessing cardiac involvement. The biologic agents, such as the anti-tumor necrosis factor antibodies, have changed the approach to refractory sarcoidosis. There is increasing evidence that the clinician can identify which patient is most likely to benefit from such therapy. As new and more potent antiinflammatory agents have been developed, it is clear that there are other factors that burden the patient with sarcoidosis, including fatigue and sarcoidosis-associated pulmonary hypertension. There have been several recent studies demonstrating treatment options for these problems.

show abstract

Section: Diagnosismentioning

confidence: 99%

A Concise Review of Pulmonary Sarcoidosis

Baughman

Culver²,

Judson

2011

Am J Respir Crit Care Med

438

330

View full text Add to dashboard Cite

show abstract

“…In comparison to other serum markers, it appears to be as predictive of disease activity [33,34]. It has also been found to be complimentary to FDG PET scanning by other authors [35].…”

mentioning

confidence: 69%

Relapses of sarcoidosis: what are they and can we predict who will get them?

Baughman

Judson

2014

Eur Respir J

View full text Add to dashboard Cite

“…It is an interesting fact that sIL2-Rα is an established marker in human medicine for diagnosis and progression of many tumorous diseases [6,8,9,23], but does not have huge relevance as a marker for inflammation in non-tumorous diseases. There are two exceptions: rheumatoid arthritis [24] and human visceral leishmaniasis [18].…”

Section: Discussionmentioning

confidence: 99%

“…They include malignant melanoma, carcinomas of the kidney and different tumors of the head, neck an oesophagus as well as lung cancer [6,7]. There is a strong correlation between increased serum levels of sIL-2Rα and the severity of disease in patients with a pulmonary sarcoidosis [8]. Since this correlation was found sIL-2Rα is used routinely as a marker for the diagnose and progression of sarcoidosis.…”

Section: Introductionmentioning

confidence: 99%

Soluble Interleukin 2 Receptor-Alpha (sIL-2Rα) in the Peripheral Blood of Dogs—Comparison of Malignant Neoplasia with Other Diseases

Prachar¹,

Kaup²,

Neumann

2013

OJVM

View full text Add to dashboard Cite

Background: Cytokines are mediators of diseases. Expression levels in the blood could be of clinical relevance. Objective: sIL-2Rα is used as a marker for different malignancies in human medicine. The aim of this study was to show if sIL-2Rα is detectable and if there is any correlation to different diseases in dogs. Methods: For this purposes sIL-2Rα concentrations in the blood were measured in healthy dogs, in dogs with different non-neoplastic diseases and benign tumors and in dogs with malignant tumors. Serum levels of sIL-2Rα were measured by using a human specific enzyme linked immunosorbent assay (ELISA). Results: Measurement of sIL-2Rα was successful in most of the samples. Dogs with diseases have significantly increased serum levels of sIL-2Rα compared to healthy controls. sIL-2Rα serum levels are higher in patients with non-neoplastic diseases and benign tumors than in those with malignant neoplasia. There is a strong correlation between sIL-2Rα and leukocyte count. Conclusion: Measurements of sIL-2Rα in serum may be helpful in detecting stages and grades of inflammation in the progression of disease. sIL-2Rα could actually not be used as an indicator for malignant diseases in dogs like in humans. The strong correlation between sIL-2Rα and the leukocyte count indicates the inflammatory response to the disease. This could be helpful in giving a prognosis in some cases, because the inflammatory reaction is of prognostic relevance in different diseases including malignant and non-malignant neoplasia. Although the results of our research studies were very promising, further studies should be performed with a canine ELISA.

show abstract

Chitotriosidase and soluble IL‐2 receptor: Comparison of two markers of sarcoidosis severity

Abstract: Chitotriosidase and sIL-2R are two markers of sarcoidosis of different origin, the values of which show a correlation in these patients; they are easily detectable in serum and could be useful clinical markers of progression.

Cited by 59 publications

References 24 publications

A Concise Review of Pulmonary Sarcoidosis

A Concise Review of Pulmonary Sarcoidosis

Relapses of sarcoidosis: what are they and can we predict who will get them?

Soluble Interleukin 2 Receptor-Alpha (sIL-2Rα) in the Peripheral Blood of Dogs—Comparison of Malignant Neoplasia with Other Diseases

Contact Info

Product

Resources

About